Skip to content
MASLD 2024

Event Information:


June 24th and 25th, 2024


London, United Kingdom

Related Models

Humanized Liver Mouse Model, Humanized Mouse Models

TransCure BioServices at the 7th Global MASLD Congress 2024: Leading the Fight Against Liver Disease

TransCure BioServices is proud to announce our participation in the 7th Global MASLD Congress, to be held on June 24-25, 2024, at the London Heathrow Marriott. This essential gathering brings together the leading minds in the study of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic associated steatohepatitis (MASH), conditions that continue to challenge the medical community due to their complex pathogenesis and lack of approved pharmaceutical treatments.

The rising incidence of MASLD and MASH underscores the urgent need for innovative diagnostic and therapeutic approaches. The Global MASLD Congress is at the forefront of addressing these challenges, offering insights into promising clinical developments and novel diagnostic tools that are reshaping the landscape of liver disease treatment.

Join Ha-Yeon Kim-Penard, PhD, Scientist Business Developer, and Clothilde Philouze, PhD, R&D Project Leader, to learn about our latest advancements in preclinical humanized liver mouse models that are crucial for pre-clinical research in liver diseases. Our team is looking forward to engaging with peers, discussing potential collaborations, and exploring how our innovative solutions can support ongoing and future research projects.

Whether you are looking to advance your knowledge, showcase your latest research, or find partners for future collaborations, the Global MASLD Congress is an event not to be missed. We invite all stakeholders involved in liver disease research and treatment to join us at this significant event.

We look forward to welcoming you to London and joining hands in the fight against liver disease.

See you at the Global MASLD Congress 2024!

Ha-Yeon Kim-Penard, PhDAttending in person for TransCure bioServices:

Ha-Yeon Kim-Penard, PhD, Business Development

Ha-Yeon Kim-Penard holds a PhD in Cell and Molecular Biology from the University of Paris, in France. She worked at the Curie Institute (Orsay, France) in the field of cancer biology in cutaneous melanoma, before joining the TransCure bioServices Team as Project Leader in 2020. She has led many in vivo preclinical projects encompassing immuno-oncology, infectious diseases, inflammatory diseases in humanized Immune System and humanized liver mouse models.

Clothilde PhilouzeAttending in person for TransCure bioServices:

Clothilde Philouze, PhD, R&D Project Leader

Clothilde Philouze earned her PhD in Biology through her translational research on cardiometabolic diseases, with a specific focus on the development of cardiomyopathy in the context of diabetes. Following her Ph.D., she worked as a postdoctoral researcher in the Cardiovascular and Metabolic Diseases Research Department at Servier. She then transitioned to TransCure bioServices, where she now serves as an R&D Project Leader. Clothilde contributes to the development of innovative models of metabolic and inflammatory diseases in mice with humanized immune systems and humanized livers, with a particular emphasis on MAFLD (Metabolic Associated Fatty Liver Disease).

This event has concluded